Company Overview
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +0.00% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NUVL Nuvalent Inc R2KPHARMA | 123.96 | -20.46 | $9.12B | 0.00% | -31.35% | -41.19% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -4.01M | -4.04M | -6.16M | -9.85M | -12.43M | -17.69M | -18.73M | -20.39M | -30.21M | -34.06M | -38.78M | -52.59M | -65.15M | -76.33M | -94.81M | -104.57M | -112.70M | -119.41M |
| Net Income | 5.36M | -8.56M | -4.78M | -6.79M | -9.84M | -12.43M | -17.55M | -18.47M | -19.72M | -25.19M | -29.09M | -33.65M | -44.48M | -57.17M | -84.34M | -84.58M | -99.65M | -122.44M | -109.28M |
| Diluted EPS | - | -2.82 | -1.57 | -2.20 | -3.17 | -0.39 | -0.36 | -0.38 | -0.41 | -0.44 | -0.51 | -0.59 | -0.69 | -0.88 | -1.28 | -1.18 | -1.39 | -1.70 | -1.39 |
| R&D Expense | - | 3.66M | 3.72M | 5.48M | 7.83M | 9.05M | 12.69M | 13.56M | 14.62M | 22.12M | 25.92M | 29.61M | 38.63M | 49.17M | 60.55M | 74.42M | 80.91M | 83.84M | 83.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -16.91M | -45.82M | -86.11M | -149.49M | -280.37M | -414.31M |
| Net Income | -14.56M | -46.34M | -81.85M | -126.22M | -260.76M | -425.38M |
| Diluted EPS | -5.08 | -2.13 | -1.65 | -2.17 | -3.93 | -5.85 |
| R&D Expense | 15.40M | 35.56M | 63.73M | 113.24M | 217.77M | 306.97M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 10.65M | 293.82M | 482.46M | 732.38M | 1.14B | 1.41B |
| Total Equity | -17.26M | -31.32M | 285.04M | 462.98M | 700.56M | 1.07B | 1.25B |
| Cash & Equivalents | 3.02M | 10.33M | 68.53M | 241.81M | 335.39M | 145.69M | 261.75M |
| Total Liabilities | - | 6.62M | 8.79M | 19.48M | 31.82M | 71.96M | 164.37M |
| Current Liabilities | - | 4.38M | 8.79M | 19.48M | 31.82M | 54.02M | 91.17M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.95M | -40.00M | -64.97M | -99.74M | -185.06M | -275.21M |
| Investing Cash Flow | - | -220.03M | -10.66M | -143.53M | -573.51M | -124.08M |
| Financing Cash Flow | 22.27M | 318.22M | 248.92M | 336.85M | 568.88M | 515.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 46.5% | -16.3% | -17.7% | -18.0% | -24.4% | -34.1% |
| ROCE % | -269.8% | -16.1% | -18.6% | -21.3% | -25.8% | -31.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Deerfield Management Company, L.P | 23.45% | 17.25M | $2.14B |
| 2 | FMR, LLC | 12.61% | 9.27M | $1.15B |
| 3 | Paradigm Biocapital Advisors LP | 7.24% | 5.32M | $660.02M |
| 4 | Blackrock Inc. | 6.56% | 4.82M | $598.08M |
| 5 | JPMORGAN CHASE & CO | 4.20% | 3.09M | $382.83M |
| 6 | RA Capital Management, L.P. | 3.44% | 2.53M | $314.13M |
| 7 | Vanguard Portfolio Management LLC | 3.40% | 2.50M | $310.01M |
| 8 | Wellington Management Group, LLP | 3.36% | 2.47M | $306.24M |
| 9 | Vanguard Capital Management LLC | 3.30% | 2.43M | $301.04M |
| 10 | Price (T.Rowe) Associates Inc | 2.80% | 2.06M | $254.88M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NUVL
NUVL Stock Surges 39% Premarket – Why Is GSK Buying This Boston-Based Oncology Company? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNWklEMFNCVXFtaFJ5VEJrWFZ1dEJyeGJKbkZqZzBzcG1tbWNFU19FSFFvM05HRkJUN3pSd01KSmtNZjBMLW9rd2JxU01LSEdzeFQ3TWxqTDBEZWpfbm84NkczTjNuWEFJMUt1RjU3dzRyTGJVU1pnUjcyd1N0bDE3NkZseGJQd1dMRWlMbj…
Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQVVJia1pIUHJXb0o1aU9pZzlRb2FzVGRUbWJFakYzeFdiQTF2TUlPOUFXcGNIUXZYcGh5ckN0cGhoa1drbGN4M1BiQjdYMXhlamFLQTRLb1FnTEhaRWtwOWh6ckRZa0xYSElyVUNSNUtUTzF4dDFJMHBvTGRaRFVnR3lLMmtUa3pCa015am…
Nuvalent Inc-A (NASDAQ:NUVL) Stock Edges Higher After Q1 2026 Earnings Miss as Investors Focus on Pipeline Milestones - ChartMill
<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxOS0hYQ01GYl9zT2dvZ2ZxM0hFTngwNUM4RFVxazRHS0RaUlQ0UVExajZab2pLSVdaU0lxZFZ2dllTY3NKR0NDMW1KTlJpRFR4UnAtLVB6aEgteUlaYlpkZnFRUnB0VVdZZmpCZ0UtWW9OLU54aE5XRDdpcHlXd2dOVVFUOWpLNE5HOVBhZn…
NUVL Stock Surges 39% Premarket – Why Is GSK Buying This Boston-Based Oncology Company? - TradingView
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxOczl4eEJCelhGUlRYOTVoVzN6SGR6NXBEbWFLclVVTGFIYXd5OFVmeDZmaUt1TEtlVXdhVUxseVhyRXEzVExhZkFBbDZyOWJaZmhOenhpcjdLZEh4ckI5bWtUbllSeGFtb3hub1F2dERvanZxc2x6TzFPZjQ4TnJtS1ZBOHQzWDJTQ3dRbz…
Nuvalent Catapults To Record High On GSK's $10.6 Billion All-Cash Bid - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE5BS0dVcGhOTjZ3Ukt3ZFg2aFg1S1RmOVFpdDBLdmo0dUtFbF9FMy1UWEZ6MENEbFNTQmlNVGhEbTBoeUdBM2k0TnBpXzZNa291eEV4Y0xxLVkxNEhIZjB3T09aTW9IcFhfSHJwTXE3WDZyTkwtUzBXdEtoamJSZw?oc=5" target="_blan…
Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOLUR2NXRXbXBEZlctbUVOeENENjNnRGNxRXVucWJ3Z1ZCT1IzUUFaT1hDSnFjVzFUbDQ5NndjYkY2SjVxa3NfRWlLZU0yVy1GRW5VQ29BWllYa0hhWnhCWHl4SnFlZnJHNk8zaVNhZG9SRTNSbWlnS1NCdGhwVVJjM3dlam45N0tqQTlQTk…
NUVL — Frequently Asked Questions
What is the current share price of Nuvalent Inc (NUVL)?
As of 2026-10-23 16:27 PDT, Nuvalent Inc (NUVL) trades at $123.96 on NasdaqGS. Its 52-week range is $123.96 to $123.96.
What is the market capitalisation of NUVL?
Nuvalent Inc (NUVL) has a market capitalisation of $9.12B on NasdaqGS.
What is the P/E ratio of NUVL?
NUVL trades at a trailing price-to-earnings (P/E) ratio of -20.46. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 8.33.
What is the return on equity (ROE) of NUVL?
NUVL has a return on equity (ROE) of -41.19%. Its return on capital employed (ROCE) is -31.35%.
Is NUVL a good stock to buy?
This page provides a data-driven analysis of Nuvalent Inc (NUVL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.